Dr. Alberto Mussetti's current clinical and research work is at the Hematology Dept. of the Catalan Institute of Oncology (ICO) - Hospital Duran i Reynals, Barcelona (Dept. Head: Anna Sureda, MD, PhD). He has received clinical training in the management of patients treated with CAR therapy at Memorial Sloan Kettering Cancer Center (New York, 2013-2014). During this period, he also collaborated at the Brenier Brentjens laboratory, one of the first entities to produce CAR T cells for patients affected with CD19-positive malignancies. In 2016, Dr. Mussetti was in charge of the clinical management of the first adult Italian patient treated with anti-CD19 CARTs in the setting of relapsed/refractory diffuse large B-cell lymphoma (JULIET trial, https://www.ncbi.nlm.nih.gov/pubmed/30501490). In 2018 he moved to ICO-Barcelona to start the CAR therapy program there. At ICO he has treated CAR patients in the commercial setting but also in the context of clinical trials (ZUMA7 and BELINDA). He is also collaborating with the lymphoma and cell therapies committees of the European Bone Marrow Transplantation Society (EBMT) and the Center for International Bone Marrow Transplant Research (CIBMTR) in proposing registry studies dealing with lymphomas and cell therapies. He has already participated at this level as collaborator or principal investigator (https://www.ncbi.nlm.nih.gov/pubmed/26670632). At the national level he recently won a competitive grant for CAR clinical research sponsored by GILEAD Research Scholars Program (http://ico.gencat.cat/es/detall/noticia/Nova-Noticia-03911) as PI and Coordinator among the study researchers. In case of promising preclinical results, he will be in charge of the clinical development of this cell therapy.

Major fields of interest:

Lymphoma and myeloma treatment, including high dose chemotherapy, stem cell transplantation and clinical development of novel agents including immunotherapies

Haploidentical stem cell transplantation and development of novel GVHD prophylaxis including post-transplant cyclophosphamide